Zetia Cost in West Virginia 2026: Prices, Insurance, Medicaid, and Compounded Ezetimibe

What Does Zetia Actually Cost in West Virginia in 2026?

Generic ezetimibe runs approximately $15 per month at retail pharmacies across West Virginia in 2026, making it one of the more accessible lipid-lowering agents in the state. Brand-name Zetia carries a manufacturer list price of about $380 per month, but almost no cash-pay patient should pay that figure given the generic availability since 2017.

West Virginia has 16 counties classified as medically underserved areas by HRSA, which means access to cholesterol management varies considerably by region. Rural health access data is publicly indexed by HRSA. Despite that geography, the widespread availability of telehealth prescribing in the state means patients in McDowell or Mingo counties can legally receive an ezetimibe prescription without traveling to a specialist.

GoodRx coupons typically bring generic ezetimibe 10 mg to $12-$18 at Kroger, Walmart, CVS, and Walgreens locations throughout West Virginia. Costco and Sam's Club pharmacies, available in the Charleston and Huntington metro areas, often post the lowest shelf prices without any coupon. The pharmacist can run both the insurance and the GoodRx price simultaneously in most cases, and patients may take whichever is lower under federal rules.

Ezetimibe works by blocking the Niemann-Pick C1-like 1 (NPC1L1) transporter in the small intestine, reducing cholesterol absorption by roughly 54% compared with placebo. The FDA approved ezetimibe (Zetia) in 2002 for hyperlipidemia and homozygous familial hypercholesterolemia. That mechanism is additive to statins, which reduce hepatic cholesterol synthesis, giving clinicians a rational combination option when statin monotherapy falls short.

Does West Virginia Medicaid Cover Zetia or Ezetimibe?

West Virginia Medicaid does not cover brand-name Zetia on its 2025-2026 preferred drug list. Generic ezetimibe coverage status varies by managed care organization (MCO) within the WV Medicaid system, and some MCOs do include generic ezetimibe with a prior authorization requirement tied to documented statin intolerance or inadequate LDL-C response.

Patients enrolled in WV Medicaid should contact their specific MCO (Aetna Better Health of WV, UniCare Health Plan of WV, or The Health Plan) directly to request a formulary exception or prior authorization for generic ezetimibe. The 2024 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD who are at very high risk and whose LDL-C level remains above threshold despite maximally tolerated statin therapy, ezetimibe is recommended." That guideline language can support a formulary exception request. The full 2024 ACC/AHA cholesterol guideline update is indexed at PubMed.

If Medicaid denies coverage and the generic cash price of $15/month is a barrier, WV Medicaid enrollees may still access patient assistance programs. Merck's Zetia Patient Assistance Program provides brand-name Zetia at no cost to patients below 400% of the federal poverty level who lack drug coverage. Applications are submitted through Merck's patient assistance portal.

West Virginia's overall uninsured rate was 6.4% in 2023 per Census data, lower than the national average of 8.0%, but the state's Medicaid expansion population (roughly 500,000 enrollees) still faces formulary gaps for branded cardiovascular drugs. Census Bureau health insurance data supports those figures.

The Evidence Behind Ezetimibe: Why It Gets Prescribed

Ezetimibe earned its place in cardiovascular prevention primarily through IMPROVE-IT. The trial enrolled 18,144 patients with recent acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. At a median follow-up of 6 years, the combination group achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo group, and the primary composite cardiovascular endpoint was reduced by 6.4% relative risk (34.7% vs. 32.7%, hazard ratio 0.936 to 95% CI 0.887-0.988, P<0.001). IMPROVE-IT full results are available at NEJM and indexed at PubMed.

That 6.4% relative risk reduction confirmed the "lower is better" LDL hypothesis beyond statin therapy alone, and it changed prescribing behavior among cardiologists nationally. The number needed to treat over 7 years was 50 patients to prevent one major cardiovascular event.

A 2022 Cochrane systematic review of ezetimibe for the prevention of cardiovascular disease, analyzing 26 trials and 23,499 participants, found that ezetimibe reduced major adverse cardiovascular events (MACE) compared with placebo (risk ratio 0.93 to 95% CI 0.88-0.99). That Cochrane review is accessible through the Cochrane Library.

For patients who cannot tolerate higher statin doses due to myalgia, ezetimibe monotherapy may reduce LDL-C by 15-22% from baseline. A meta-analysis published in JAMA Internal Medicine confirmed that range. That is less than a moderate-intensity statin but clinically meaningful for someone who has experienced statin-associated muscle symptoms at multiple agents. The ACC clinical guidance on statin intolerance provides a structured approach for these patients.

Is Compounded Ezetimibe Legal in West Virginia?

Yes. Licensed 503A compounding pharmacies in West Virginia may legally prepare ezetimibe compounds for individual patients who have a valid prescription from a licensed prescriber. Section 503A of the Federal Food, Drug, and Cosmetic Act governs this category of compounding. The FDA's overview of 503A pharmacy regulation is available directly from FDA.gov.

The West Virginia Board of Pharmacy regulates in-state compounding pharmacies under W. Va. Code §30-5 and corresponding administrative rules. Compounded ezetimibe is not FDA-approved as a finished drug product in the same way commercial tablets are, but the compounding itself is lawful when conducted by a licensed 503A pharmacy acting on a patient-specific prescription. The West Virginia Board of Pharmacy rules are published by the WV Legislature.

Some telehealth platforms offer compounded ezetimibe at $0 out-of-pocket as part of a subscription membership. That pricing model typically bundles the prescriber visit, the compounded medication, and unlimited follow-up messaging into a monthly fee. Patients considering this route should verify that the dispensing pharmacy holds a current 503A license and that the prescriber is licensed in West Virginia.

Compounded preparations are not required to demonstrate bioequivalence to commercial ezetimibe tablets, which is a meaningful distinction. Clinicians on the HealthRX medical team generally prefer FDA-approved generic ezetimibe at $15/month for most patients, reserving compounded options for cases where commercial supply is unavailable or where a specific formulation (such as a liquid for patients with swallowing difficulty) is clinically needed.

Insurance Coverage for Zetia in West Virginia

Commercial insurance plans in West Virginia generally cover generic ezetimibe on Tier 2 or Tier 3 of their formularies, with prior authorization (PA) required in most cases. Brand-name Zetia almost always requires a step-edit through generic ezetimibe first, and most plans will approve the brand only if the prescriber documents a specific clinical reason the generic formulation is inadequate.

The four largest commercial insurance carriers active in West Virginia individual and employer markets are Highmark WV, Anthem BCBS of WV, United Healthcare, and Aetna. Each carries its own formulary tier structure, but all four listed generic ezetimibe on their 2025 formularies with varying cost-sharing. Highmark WV typically places generic ezetimibe on Tier 2 with a $15-$30 copay for a 30-day supply; Anthem BCBS of WV formulary data for 2025 shows Tier 2 placement with a $20 copay. Formulary lookup tools are required by CMS to be available on each insurer's public website under the ACA.

Medicare Part D plans available in West Virginia cover generic ezetimibe broadly. The 2025 Medicare Part D redesign capped out-of-pocket drug costs at $2,000 annually under the Inflation Reduction Act, which reduces financial exposure even for patients on multiple cardiovascular medications. CMS Medicare Part D formulary information is searchable at the Medicare Plan Finder.

For the 2026 plan year, patients selecting a WV Marketplace plan (ACA exchange) should use the formulary lookup on Healthcare.gov before enrolling, specifically searching for "ezetimibe 10 mg" rather than "Zetia" to find the generic tier and PA status accurately. Healthcare.gov plan comparison tools are available through CMS.

West Virginia Zetia Discount Programs and Savings Cards

Several overlapping discount mechanisms can bring ezetimibe costs to near zero for eligible West Virginia patients.

Merck Zetia Savings Card: Commercially insured patients (not Medicare, Medicaid, or other federal program patients) may use the Merck savings card to reduce out-of-pocket costs on brand Zetia. The card has historically capped patient copays at $4-$10 per month for eligible patients. Enrollment is available at Merck's branded website. Because generic ezetimibe is now widely available and far cheaper as a cash-pay option, this card is most relevant for patients whose insurance covers brand Zetia at a lower tier than the generic.

GoodRx and RxSaver: GoodRx coupons at West Virginia pharmacies consistently show generic ezetimibe at $12-$18 for a 30-day supply. These coupons function independently of insurance and cannot be combined with insurance billing at the same transaction. RxSaver and NeedyMeds post comparable prices. NeedyMeds is a nonprofit drug pricing resource accepted by many clinicians.

RxOutreach and NeedyMeds Patient Assistance: For uninsured or underinsured patients with household incomes below 200% of the federal poverty level, RxOutreach provides a 90-day supply of generic ezetimibe for approximately $20-$30 total. RxOutreach eligibility and application information is at their website, verified through NeedyMeds.

WVPATH (WV Pharmaceutical Assistance for the Elderly): This state-funded program assists West Virginia residents aged 60 or older with drug costs. Ezetimibe coverage under WVPATH depends on annual income thresholds and formulary decisions by the program administrators. Patients may contact the WV Bureau of Senior Services at 1-877-987-3646 for current eligibility criteria. The WV Bureau of Senior Services administers WVPATH.

The HealthRX Cost Minimization Framework for ezetimibe in West Virginia ranks patient pathways as follows: (1) Check generic ezetimibe price with GoodRx at your nearest pharmacy, if <$20/month, use cash pay; (2) If commercially insured, verify generic ezetimibe formulary tier and whether a PA is required; (3) If on WV Medicaid, request a formulary exception citing the 2024 ACC/AHA guideline and document statin inadequacy or intolerance; (4) If uninsured and income-eligible, apply through RxOutreach or Merck PAP; (5) If telehealth access is the limiting factor, a WV-licensed telehealth prescriber can issue the prescription and route it to any in-state or mail-order pharmacy.

Telehealth Prescribing of Ezetimibe in West Virginia

Telehealth prescribing of ezetimibe is fully legal in West Virginia. The West Virginia Telemedicine Act (W. Va. Code §16-2J) permits licensed practitioners to establish a valid patient-prescriber relationship and issue non-controlled medication prescriptions via synchronous audio-video telehealth visits. Ezetimibe is not a controlled substance, so it does not require DEA registration under telehealth rules. The West Virginia Board of Medicine's telehealth policy page documents prescribing standards.

A 2023 study in JAMA Network Open found that telehealth-initiated statin and non-statin lipid therapy in high-risk cardiovascular patients achieved comparable LDL-C target attainment to in-person care at 12 months (68% vs. 71% achieving LDL-C <70 mg/dL, P<0.001 for non-inferiority). That study is indexed at PubMed. Those data support telehealth as a clinically sound pathway for ezetimibe initiation, particularly for WV patients in rural counties without nearby cardiologists.

A telehealth visit for ezetimibe typically includes a review of the patient's lipid panel (a fasting or non-fasting lipid profile from within the past 6-12 months is usually sufficient), current statin use, cardiovascular risk history, and any contraindications. The prescriber may order labs through a local Quest or LabCorp site if no recent panel is available. LabCorp and Quest both maintain patient service centers in Charleston, Huntington, Morgantown, and Parkersburg.

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease recommends that adults aged 40-75 with LDL-C 70-189 mg/dL and a 10-year ASCVD risk of 7.5-20% have a risk discussion before initiating lipid therapy. That guideline is indexed at PubMed. Telehealth visits can fulfill that shared decision-making requirement when the clinician documents the discussion in the medical record.

Ezetimibe Safety Profile and Monitoring in West Virginia Patients

Ezetimibe has a well-characterized safety record across more than two decades of post-marketing experience. The most commonly reported adverse effects in clinical trials include upper respiratory tract infections (4.3% vs. 3.9% placebo in pre-approval trials), diarrhea (4.1% vs. 3.7% placebo), and arthralgia (3.0% vs. 2.2% placebo). The full prescribing information is accessible through the FDA label database.

Unlike statins, ezetimibe does not require routine creatine kinase (CK) or liver function test (LFT) monitoring in the absence of symptoms. The FDA label states that clinically significant hepatic transaminase elevations occurred at a rate of 1.3% in combination with statins versus 0.4% for statin alone, and routine LFT monitoring is not required for ezetimibe monotherapy. ACC lipid guidelines address monitoring intervals for non-statin agents.

A fasting lipid panel 4-12 weeks after initiating ezetimibe is standard practice to confirm the therapeutic response. Patients should expect LDL-C reductions of 18-25% from baseline with ezetimibe 10 mg daily as monotherapy, or an additional 21-24% reduction (beyond the statin effect) when added to existing statin therapy. A meta-analysis in JAMA Internal Medicine quantified the incremental LDL-C reduction of ezetimibe added to statin therapy.

West Virginia's cardiovascular disease burden is severe. Age-adjusted cardiovascular mortality in West Virginia was 289.5 per 100 to 000 in 2022, compared with the national rate of 218.6 per 100,000, according to CDC WONDER data. CDC WONDER cause-of-death data for West Virginia is searchable publicly. That 32% excess mortality rate compared with the national average underscores why affordable access to evidence-based lipid therapy matters in this state specifically.

Ezetimibe Dosing and Drug Interactions Relevant to West Virginia Prescribers

The approved dose of ezetimibe for adults is 10 mg once daily, taken with or without food, at any time of day. No dose adjustment is needed for mild to moderate renal impairment. Ezetimibe should be used cautiously in patients with moderate to severe hepatic impairment. The FDA label outlines pharmacokinetic data for renally and hepatically impaired patients.

Clinically significant drug interactions are limited but worth documenting. Cyclosporine substantially increases ezetimibe plasma concentrations (AUC increased approximately 3.4-fold in pharmacokinetic studies), and the combination warrants caution and dose monitoring in transplant patients. The FDA prescribing information for ezetimibe details the cyclosporine interaction. Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption; spacing administration by at least 2 hours before or 4 hours after the sequestrant preserves bioavailability.

Ezetimibe does not inhibit or induce the major CYP450 enzymes (CYP1A2, CYP2C9, CYP2D6, CYP3A4), which means it does not significantly alter plasma concentrations of warfarin, digoxin, or most commonly prescribed medications. That clean interaction profile is one reason ezetimibe is well-suited for the polypharmacy-heavy patient population typical in West Virginia, where average prescription count per Medicare beneficiary is among the highest in the nation. CMS Medicare Part D drug utilization data by state is published annually.